Hikma 2026 outlook

Hikma Pharmaceuticals Maintains 2026 Outlook Despite Middle East War Cost Pressures

Hikma Pharmaceuticals reaffirmed its 2026 financial guidance, expressing confidence in absorbing Middle East war-related cost increases. The UK drugmaker also decided to close its 503B compounding bus